Natamycin
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 665.73 |
Cas No. | 7681-93-8 |
Formula | C33H47NO13 |
Solubility | insoluble in EtOH; insoluble in H2O; ≥16.43 mg/mL in DMSO with gentle warming |
SDF | Download SDF |
Canonical SMILES | O[C@](C1)(C[C@H](C[C@H]2O[C@@H]2/C=C\C(O[C@H](C)C/C=C\C=C/C=C\C=C/[C@@H]3O[C@@H]([C@H]([C@H]4N)O)O[C@H](C)[C@H]4O)=O)O)O[C@](C3)([H])[C@H](C(O)=O)[C@H]1O |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Cell experiment [1]: | |
Cell lines |
human corneal epithelial cells(HCE) |
Preparation method |
Soluble in DMSO > 10.75 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
5 μM of FITC(Fluorescein isothiocyanate) labelled natamycin for 1 h at 37°C |
Applications |
The drug natamycin had a broad spectrum activity against filamentous fungi in the HCE, therefore, it was considered as the drug of choice for the treatment of filamentous fungi associated Keratitis. |
Clinical experiment [2]: | |
Disease models |
Patients with smear positive or culture-positive filamentous fungal corneal ulcers |
Dosage form |
5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks |
Application |
Topical natamycin was superior to topical voriconazole for the treatment of filamentous fungal corneal ulcers, and in particular those culture-positive for Fusarium species. Vision-related functioning was higher among those treated with natamycin compared with voriconazole. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Jain A1, Shah SG, Chugh A, Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis. Pharm Res. 2015 Jun;32(6):1920-30. doi: 10.1007/s11095-014-1586-x. Epub 2014 Dec 3. [2]. Rose-Nussbaumer J1,2,3, Prajna NV4, et al, Risk factors for low vision related functioning in the Mycotic Ulcer Treatment Trial: a randomised trial comparing natamycin with voriconazole. Br J Ophthalmol. 2016 Jul;100(7):929-932. doi: 10.1136/bjophthalmol-2015-306828. Epub 2015 Nov 3. |
Quality Control & MSDS
- View current batch: